Literature DB >> 32185705

Molecular and Cellular Functions of CTLA-4.

Samya Van Coillie1, Bartosz Wiernicki2, Jie Xu3.   

Abstract

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an inhibitory receptor belonging to the CD28 immunoglobulin subfamily, expressed primarily by T-cells. Its ligands, CD80 and CD86, are typically found on the surface of antigen-presenting cells and can either bind CD28 or CTLA-4, resulting in a costimulatory or a co-inhibitory response, respectively. Because of its dampening effect, CTLA-4 is a crucial regulator of T-cell homeostasis and self-tolerance. The mechanisms by which CTLA-4 exerts its inhibitory function can be categorized as either cell-intrinsic (affects the CTLA-4 expressing T-cell) or cell-extrinsic (affects secondary cells). Research from the last decade has shown that CTLA-4 mainly acts in a cell-extrinsic manner via its competition with CD28, CTLA-4-mediated trans-endocytosis of CD80 and CD86, and its direct tolerogenic effects on the interacting cell. Nonetheless, intrinsic CTLA-4 signaling has been implicated in T-cell motility and the regulation of CTLA-4 its subcellular localization amongst others. CTLA-4 is well recognized as a key immune checkpoint and has gained significant momentum as a therapeutic target in the field of autoimmunity and cancer. In this chapter, we describe the role of costimulation in immune response induction as well as the main mechanisms by which CTLA-4 can inhibit this process.

Entities:  

Keywords:  CD28; CD80; CD86; CTLA-4; Immune tolerance

Year:  2020        PMID: 32185705     DOI: 10.1007/978-981-15-3266-5_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  26 in total

1.  Occupational Low-Dose Radiation Affects the Expression of Immune Checkpoint of Medical Radiologists.

Authors:  Chen Wang; Changfu Hao; Kai Dai; Yuzheng Li; Jie Jiao; Zhuoya Niu; Xiao Xu; Xuedan Deng; Jing He; Wu Yao
Journal:  Int J Environ Res Public Health       Date:  2022-06-09       Impact factor: 4.614

Review 2.  Cervical Cancer Immunotherapy: Facts and Hopes.

Authors:  Louise Ferrall; Ken Y Lin; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  Clin Cancer Res       Date:  2021-04-22       Impact factor: 12.531

Review 3.  Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.

Authors:  Aaron Lerner; Carina Benzvi
Journal:  Biomedicines       Date:  2022-03-04

4.  SIRT1 and gynecological malignancies (Review).

Authors:  Jiayu Chen; Houzao Chen; Lingya Pan
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

Review 5.  Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.

Authors:  M Jamee; S Hosseinzadeh; N Sharifinejad; M Zaki-Dizaji; M Matloubi; M Hasani; S Baris; M Alsabbagh; B Lo; G Azizi
Journal:  Clin Exp Immunol       Date:  2021-05-03       Impact factor: 5.732

Review 6.  Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.

Authors:  Marta Wagner; Monika Jasek; Lidia Karabon
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

Review 7.  Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors.

Authors:  Kanishka Rangamuwa; Tracy Leong; Clare Weeden; Marie-Liesse Asselin-Labat; Steven Bozinovski; Michael Christie; Tom John; Phillip Antippa; Louis Irving; Daniel Steinfort
Journal:  Transl Lung Cancer Res       Date:  2021-06

Review 8.  The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy.

Authors:  Guirong Liu; Manman Liu; Junjuan Wang; Yao Mou; Huilian Che
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

Review 9.  Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity.

Authors:  Huey-Jen Lin; Yingguang Liu; Denene Lofland; Jiayuh Lin
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

Review 10.  Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.

Authors:  Peng Ye; Xiaoxia Chi; Jong-Ho Cha; Shahang Luo; Guanghui Yang; Xiuwen Yan; Wen-Hao Yang
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.